Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

About this update from Organogenesis Holdings Inc.

CANTON, Mass. , Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2023 financial results will be reported after the market closes on Thursday, November 9th . Management will host a conference call at 5:00 p.m. Eastern Time on November 9th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here , or access the teleconference here . The live webcast can also be accessed via the company’s website at investors.organogenesis.com . The webcast will be archived on the company website for approximately one year. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com . Investor Inquiries: ICR Westwicke Mike Piccinino , CFA [email protected] Press and Media Inquiries: Organogenesis Ron O’Brien [email protected] Source: Organogenesis Holdings Inc.

View stock analysis, news, and events for Organogenesis Holdings Inc.